• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Madrigal Pharmaceuticals Inc (NQ: MDGL )

    302.67 -12.48 (-3.96%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Madrigal Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 7 Next >
    1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
    There's a bright future ahead for this company. 
    Via The Motley Fool
    Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
    Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
    Via Benzinga
    Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Earnings Preview For Madrigal Pharmaceuticals
    Via Benzinga
    Is Madrigal Pharmaceuticals Stock a Buy?
    It's not the most prominent biotech, but it has an important claim to fame. 
    Via The Motley Fool
    Is Madrigal Pharmaceuticals Stock a Buy?
    The biotech could be worth a lot more in 10 years. 
    Via The Motley Fool
    This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
    One player's minor pain is another's moderate gain. 
    Via The Motley Fool
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
    Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. 
    Via Investor's Business Daily
    Topics Earnings
    Exposures Financial
    Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
    Will being the first to its market ensure that its future is bright? 
    Via The Motley Fool
    7 Biotech Stocks to Keep on Your Clinical Radar
    Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
    Via InvestorPlace
    Is Madrigal Pharmaceuticals a Millionaire Maker?
    Its revenue ramp-up is just starting, and its market looks lucrative. 
    Via The Motley Fool
    Is Madrigal Pharmaceuticals Stock a Buy?
    The company could become a prominent player in the biotech industry, but that might take a while. 
    Via The Motley Fool
    The Best Biotech Stock to Invest $1,000 in Right Now
    This stock may not be a slam dunk, but it's looking very promising. 
    Via The Motley Fool
    Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
    The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
    Via Investor's Business Daily
    Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
    Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade. 
    Via The Motley Fool
    Where Will Madrigal Pharmaceuticals Be in 3 Years?
    The coast is clear for it to grow, for now. 
    Via The Motley Fool
    Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
    On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
    Via Investor's Business Daily
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
    Success isn't guaranteed, but both companies could become big winners. 
    Via The Motley Fool
    What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
    Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
    Via Benzinga
    Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
    Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. 
    Via Investor's Business Daily
    DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
    Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease. 
    Via Investor's Business Daily
    The Week Ahead: What's Next
    The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
    Via Talk Markets
    MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024
    MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
    Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.